Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin in HER2-negative breast cancer brain metastases
NCT03637868Phase 2Withdrawn
- Sponsor
- Institut Paoli-Calmettes
- Start
- Feb 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in breast cancer, brain metastasis (BM), sponsored by Institut Paoli-Calmettes. Planned start Feb 2019; status: withdrawn.
02
Drugs
eribulin
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT03637868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637868.